v3.26.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
shares in Thousands, $ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Income Statement [Abstract]        
Net sales $ 2,450 $ 2,286 $ 7,106 $ 6,516
Operating expenses:        
Cost of sales 2,120 1,990 6,211 5,708
Selling, general and administrative 112 104 309 313
Amortization 0 0 1 1
Restructuring (Note 9) 22 21 68 62
Separation costs 11 7 59 14
Total operating expenses 2,265 2,122 6,648 6,098
Operating income 185 164 458 418
Interest expense (36) 0 (77) (3)
Other expense, net (Note 18) (2) 0 (9) (1)
Income before income taxes and equity income 147 164 372 414
Income tax expense (Note 13) (35) (54) (72) (104)
Income before equity income 112 110 300 310
Equity income, net of tax 0 3 9 11
Net income 112 113 309 321
Net income attributable to noncontrolling interest 10 4 11 10
Net income attributable to Versigent $ 102 $ 109 $ 298 $ 311
Earnings per share attributable to Versigent:        
Basic (in usd per share) $ 1.44 $ 1.54 $ 4.20 $ 4.39
Diluted (in usd per share) $ 1.41 $ 1.54 $ 4.16 $ 4.39
Weighted average shares outstanding:        
Basic (in shares) 70,850 70,890 70,880 70,890
Diluted (in shares) 72,250 70,890 71,670 70,890